SG11201401946QA - Methods for treating cancers using oral formulations of cytidine analogs - Google Patents
Methods for treating cancers using oral formulations of cytidine analogsInfo
- Publication number
- SG11201401946QA SG11201401946QA SG11201401946QA SG11201401946QA SG11201401946QA SG 11201401946Q A SG11201401946Q A SG 11201401946QA SG 11201401946Q A SG11201401946Q A SG 11201401946QA SG 11201401946Q A SG11201401946Q A SG 11201401946QA SG 11201401946Q A SG11201401946Q A SG 11201401946QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- oral formulations
- treating cancers
- cytidine analogs
- cytidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161554344P | 2011-11-01 | 2011-11-01 | |
PCT/US2012/062845 WO2013067043A1 (en) | 2011-11-01 | 2012-10-31 | Methods for treating cancers using oral formulations of cytidine analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201401946QA true SG11201401946QA (en) | 2014-05-29 |
Family
ID=47146759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201401946QA SG11201401946QA (en) | 2011-11-01 | 2012-10-31 | Methods for treating cancers using oral formulations of cytidine analogs |
Country Status (16)
Country | Link |
---|---|
US (2) | US9125884B2 (en) |
EP (1) | EP2773322A1 (en) |
JP (1) | JP6162709B2 (en) |
KR (1) | KR20140088603A (en) |
CN (1) | CN104168884A (en) |
AU (1) | AU2012318239B2 (en) |
BR (1) | BR112014010417A2 (en) |
CA (1) | CA2853949A1 (en) |
EA (1) | EA201490911A1 (en) |
HK (1) | HK1200716A1 (en) |
IL (1) | IL232268A0 (en) |
MX (1) | MX2014005314A (en) |
SG (1) | SG11201401946QA (en) |
TW (2) | TWI558401B (en) |
WO (1) | WO2013067043A1 (en) |
ZA (2) | ZA201403106B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009246926B2 (en) | 2008-05-15 | 2014-06-26 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
TR201807342T4 (en) | 2011-11-03 | 2018-06-21 | Millennium Pharm Inc | Administration of NEDD8 activating enzyme inhibitor and hypometylating agent. |
WO2015107105A1 (en) * | 2014-01-15 | 2015-07-23 | Apogenix Gmbh | Method of predicting the responsiveness of a cancer disease to treatment on the basis of DNA methylation |
WO2015195786A2 (en) * | 2014-06-17 | 2015-12-23 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
WO2015195634A1 (en) * | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
CN104147036B (en) * | 2014-08-24 | 2017-04-05 | 浙江大学 | Decitabine and oxaliplatin are applied in treatment renal cell carcinoma composition of medicine is prepared |
TWI716415B (en) * | 2015-06-29 | 2021-01-21 | 日商大賽璐股份有限公司 | Manufacturing method of easy-to-take solid preparation and easy-to-take solid preparation |
TWI690333B (en) * | 2015-06-29 | 2020-04-11 | 日商大賽璐股份有限公司 | Manufacturing method of easy-to-take solid preparation (with nuclear ingot) and easy-to-take solid preparation |
CN114288294A (en) * | 2015-09-01 | 2022-04-08 | 布罗德研究所股份有限公司 | Compounds and methods for treating or preventing hematologic cancers |
EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
EP3442591A4 (en) * | 2016-04-15 | 2019-11-20 | Seattle Genetics, Inc. | Combinations of cd33 antibody drug conjugates with hypomethylating agents |
WO2017210621A1 (en) | 2016-06-03 | 2017-12-07 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
EA201892746A1 (en) | 2016-06-06 | 2019-06-28 | Селджин Корпорейшн | TREATMENT OF HEMATOLOGICAL MALIGNANT TUMOR WITH THE HELP OF 2- (4-CHLOROPHENIL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXYDISOINDOLIN-5-IL) METHYL -2-2-IL) -1-OXYDISOINDOLIN-5-IL) METILE-2-IL-1-IL) -1-OXYDISOINDOLIN-5-IL) METILE-2-IL-1-IL) -1-OXYDISOINDOLIN-5-IL) METHYL 2-2-IL-1-OXYDISOINDOLIN-5-IL-ILE-2-2-IL-1-OXO-ISOINDOLIN-5-IL-ILE-2-2-IL-1-OXO-ISOINDOLIN-5-IL-ILE-2-2-IL-1-OXY-ISO-DYNDOLIN-5-IL-I-3-OXYDE |
WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
EP3481953A4 (en) * | 2016-07-06 | 2020-04-15 | Youhealth Biotech, Limited | Liver cancer methylation markers and uses thereof |
AU2018248423A1 (en) * | 2017-04-04 | 2019-10-17 | Loma Linda University | Biologic for the treatment of cancer |
CN115666588A (en) * | 2019-11-04 | 2023-01-31 | 美国杰龙生物医药公司 | Use of Janus kinase inhibitors and telomerase inhibitors for treating myeloproliferative tumors |
WO2023140691A1 (en) * | 2022-01-21 | 2023-07-27 | 주식회사 피노바이오 | Oral formulation containing 5-aza-4'-thio-2'-deoxycytidine and preparation method therefor |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (en) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | DNA encoding multipotent granulocyte colony stimulating factor |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
DE69831335T3 (en) | 1997-06-06 | 2015-01-15 | Depomed, Inc. | MAGNIFYING ORAL DOSAGE FORMS OF WATER-SOLUBLE MEDICAMENTS WITH CONTROLLED RELEASE |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
ATE340563T1 (en) | 2000-02-04 | 2006-10-15 | Depomed Inc | SHELL AND CORE TYPE DOSAGE FORM WITH A RELEASE OF ACTIVE INGREDIENTS APPROACHING TO THE ZERO ORDER |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20040162263A1 (en) | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
EP2359859A1 (en) | 2002-12-09 | 2011-08-24 | Abraxis BioScience, LLC | Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents |
US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
CA3054535A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
EP3527202A1 (en) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
US20080057086A1 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
ES2700074T3 (en) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Therapy for breast cancer based on the status of the hormone receptors with nanoparticles that comprise taxane |
US20080182806A1 (en) | 2007-01-25 | 2008-07-31 | Nevada Cancer Institute | Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents |
EP2197274A4 (en) | 2007-09-26 | 2013-03-06 | Sinai School Medicine | Azacytidine analogues and uses thereof |
JP2011505336A (en) | 2007-11-01 | 2011-02-24 | セルジーン コーポレイション | Cytidine analogs for the treatment of myelodysplastic syndrome |
JP2011517683A (en) | 2008-04-10 | 2011-06-16 | アブラクシス バイオサイエンス, エルエルシー | Composition of hydrophobic taxane derivative and use thereof |
CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
AU2009246926B2 (en) * | 2008-05-15 | 2014-06-26 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
HUE032693T2 (en) * | 2008-11-22 | 2017-10-30 | Hoffmann La Roche | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
US8492361B2 (en) | 2009-02-10 | 2013-07-23 | Celgene Corporation | Methods for treating non-small cell lung cancer using 5-azacytidine |
AU2011264590B2 (en) | 2010-06-07 | 2016-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
WO2013022872A1 (en) | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
-
2012
- 2012-10-31 MX MX2014005314A patent/MX2014005314A/en not_active Application Discontinuation
- 2012-10-31 KR KR1020147014861A patent/KR20140088603A/en not_active Application Discontinuation
- 2012-10-31 TW TW101140377A patent/TWI558401B/en not_active IP Right Cessation
- 2012-10-31 AU AU2012318239A patent/AU2012318239B2/en not_active Ceased
- 2012-10-31 TW TW105130025A patent/TW201700103A/en unknown
- 2012-10-31 EP EP12783817.5A patent/EP2773322A1/en not_active Withdrawn
- 2012-10-31 US US13/665,778 patent/US9125884B2/en not_active Expired - Fee Related
- 2012-10-31 SG SG11201401946QA patent/SG11201401946QA/en unknown
- 2012-10-31 EA EA201490911A patent/EA201490911A1/en unknown
- 2012-10-31 JP JP2014540046A patent/JP6162709B2/en active Active
- 2012-10-31 WO PCT/US2012/062845 patent/WO2013067043A1/en active Application Filing
- 2012-10-31 CA CA2853949A patent/CA2853949A1/en not_active Withdrawn
- 2012-10-31 CN CN201280065749.3A patent/CN104168884A/en active Pending
- 2012-10-31 BR BRBR112014010417-4A patent/BR112014010417A2/en not_active Application Discontinuation
-
2014
- 2014-04-27 IL IL232268A patent/IL232268A0/en unknown
- 2014-04-29 ZA ZA2014/03106A patent/ZA201403106B/en unknown
-
2015
- 2015-02-04 HK HK15101233.8A patent/HK1200716A1/en unknown
- 2015-04-16 US US14/688,623 patent/US9693987B2/en active Active
- 2015-04-28 ZA ZA2015/02909A patent/ZA201502909B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2773322A1 (en) | 2014-09-10 |
TW201325598A (en) | 2013-07-01 |
AU2012318239A1 (en) | 2013-05-16 |
CA2853949A1 (en) | 2013-05-10 |
EA201490911A1 (en) | 2014-09-30 |
BR112014010417A2 (en) | 2014-11-18 |
JP2014532704A (en) | 2014-12-08 |
US20150216886A1 (en) | 2015-08-06 |
HK1200716A1 (en) | 2015-08-14 |
US9693987B2 (en) | 2017-07-04 |
TWI558401B (en) | 2016-11-21 |
US20130109644A1 (en) | 2013-05-02 |
AU2012318239B2 (en) | 2015-07-09 |
ZA201403106B (en) | 2015-08-26 |
US9125884B2 (en) | 2015-09-08 |
WO2013067043A1 (en) | 2013-05-10 |
JP6162709B2 (en) | 2017-07-12 |
TW201700103A (en) | 2017-01-01 |
MX2014005314A (en) | 2014-09-08 |
CN104168884A (en) | 2014-11-26 |
NZ624323A (en) | 2016-07-29 |
ZA201502909B (en) | 2016-11-30 |
IL232268A0 (en) | 2014-06-30 |
KR20140088603A (en) | 2014-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201502909B (en) | Methods for treating cancers using oral formulations of cytidine analogs | |
HK1203513A1 (en) | Methods of preparing substituted nucleotide analogs | |
HK1202416A1 (en) | Compositions and methods for preventing and treating oral diseases | |
HUE051459T2 (en) | Excipients for nicotine-containing therapeutic compositions | |
IL232530B (en) | Combination of agents for treatment of cancer | |
EP2696858A4 (en) | Unit dose form for oral administration | |
EP2752198A4 (en) | Vaccine preparation for cancer treatment | |
EP2666475A4 (en) | Therapeutic agent for alopecia | |
HRP20160989T1 (en) | Solution for oral administration | |
ZA201404482B (en) | Seed treatment composition | |
ZA201303813B (en) | Methods of treatment using lipid compounds | |
GB201202773D0 (en) | Compositions for treatment of skin disorders | |
IL228908A0 (en) | Method for treatment of advanced solid tumors | |
EP2695601A4 (en) | Composition for oral cavity | |
HK1203355A1 (en) | Uses of 4-desferrithiocin analogs 4- | |
EP2780051A4 (en) | Novel enhanced formulations for coating medical devices | |
EP2668852A4 (en) | Composition for oral administration | |
HK1205519A1 (en) | Replacement therapy for dental caries | |
IL230479A0 (en) | Method for treating cancer by combined use of drugs | |
SG11201402226PA (en) | Therapeutic agent for arthrosis | |
EP2760820A4 (en) | Sphingosine analogs, compositions, and methods related thereto | |
ZA201205085B (en) | An oral treatment composition | |
ZA201205054B (en) | Apparatus for treatment of excrement | |
HU4059U (en) | Dental structure for pmplants |